Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TX
TherapeuticsMD, Inc.
TXMD
Volume
32.56K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TX
TXMD
TX
TherapeuticsMD, Inc.
TXMD
News
·
Sexual Wellness Market to Witness 4.7% CAGR by 2031 | SkyQuest Technology
Mkt Cap
$22.0M
Volume
32.56K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Sexual Wellness Market to Witness 4.7% CAGR by 2031 | SkyQuest Technology
The sexual wellness market is expected to grow at a CAGR of 4.7% by 2031, driven by increasing awareness of sexual health and the availability of a wide range of products. However, social stigma and regulatory challenges remain as key restraints.
Benzinga · Oct 3, 2024
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy
TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research · Apr 14, 2023
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · Nov 15, 2022
Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates
Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 3.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · Nov 9, 2022
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. IVERIC bio, Inc. (NASDAQ: ISEE) rose 66.3% to close at $15.70 on Tuesday after the company announced positive data from the second Phase 3 trial of Zimura (avacincaptad pegol) for geographic atrophy (GA). HyreCar Inc. (NASDAQ: HYRE) climbed 58.1% to close at $1.27 on Tuesday after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist Partners. Spero Therapeutics, Inc. (NASDAQ: SPRO) gained 55.5% to close at $1.13. Spero Therapeutics received minutes from a recent Type A meeting with the FDA, discussing steps required to resubmit the marketing application for tebipenem HBr for complicated urinary tract infection (cUTI). ChannelAdvisor Corporation (NYSE: ECOM) shares jumped 55% to settle at $22.79 after the company announced it will be acquired by CommerceHub for $23.10 per share. Akumin Inc. (NASDAQ: AKU) climbed 37% to close at $1.63. Akumin recently received notification letter from the Nasdaq confirming that company had regained compliance with minimum bid price requirement. Apexigen, Inc. (NASDAQ: APGN) rose 34.4% to close at $7.03. First Wave BioPharma, Inc. (NASDAQ: FWBI) shares gained 32.7% to close at $4.22 after gaining 7% on Friday. Galera Therapeutics, Inc. (NASDAQ: GRTX) jumped 29.5% to settle at $1.67. Galera Therapeutics, last month, posted a Q2 loss of $0.54 per share. HilleVax, Inc. (NASDAQ: HLVX) rose 24.8% to close at $17.05. HilleVax recently said Safety Data Monitoring Committee has recommended continuation of NEST-IN1 Phase 2b clinical trial. T Stamp Inc. (NASDAQ: IDAI) gained 24.6% to close at $1.72. Sunrise New Energy Co., Ltd. (NASDAQ: EPOW) jumped 24.6% to close at $3.49. Avaya Holdings Corp. (NASDAQ: AVYA) gained 24% to close at $2.12. Avalo Therapeutics, Inc. (NASDAQ: AVTX) rose 22.3% to settle at $5.87. Avalo advanced BTLA agonist fusion protein (AVTX-008) to IND-enabling stage. BioVie Inc. (NASDAQ: BIVI) rose 21.6% to close at $3.44. Ainos, Inc. (NASDAQ: AIMD) gained 21.1% to close at $2.24. Ainos recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its drug candidate VELDONA, for treatment of mild symptoms related to COVID-19. Neonode Inc. (NASDAQ: NEON) jumped 18.7% to settle at $4.26. Neonode, last month, posted a Q2 loss of $0.11 per share. Grove Collaborative Holdings, Inc. (NYSE: GROV) gained 18.4% to close at $5.80. a.k.a. Brands Holding Corp. (NYSE: AKA) surged 17.4% to settle at $2.36. SelectQuote, Inc. (NYSE: SLQT) climbed 16.8% to settle at $1.11. SelectQuote recently said Q4 sales results were lower year-over-year and issued FY23 sales guidance below analyst estimates. ADT Inc. (NYSE: ADT) rose 16.4% to close at $8.39 after the company announced it has secured investments totaling $1.5 billion from State Farm and Google. Dermata Therapeutics, Inc. (NASDAQ: DRMA) gained 15.3% to close at $0.70. Dermata Therapeutics recently posted a Q2 loss of $0.24 per share Regulus Therapeutics Inc. (NASDAQ: RGLS) gained 14.1% to close at $1.62. Regulus Therapeutics, last ...
Benzinga · Sep 7, 2022
Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday
Magic Empire Global Limited (NASDAQ: MEGL) shares climbed 80.9% to $14.87 on volatility following the company's IPO earlier this month. Viridian Therapeutics, Inc. (NASDAQ: VRDN) surged 57.7% to $23.23 after the company reported better-than-expected Q2 sales results. The company also announced initial data from the 10mg/kg cohort in its ongoing Phase 1/2 trial of VRDN-001 for thyroid eye disease (TED), a rare autoimmune disease in which the body's immune system attacks the tissues around and behind the eyes. TherapeuticsMD, Inc. (NASDAQ: TXMD) gained 22.2% to $11.25 after the company reported a profit for the second quarter and also announced better-than-expected sales results. ironSource Ltd. (NYSE:
Benzinga · Aug 15, 2022
TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript
TXMD earnings call for the period ending June 30, 2022.
The Motley Fool · Aug 15, 2022
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session
Gainers Sunrise New Energy Co. Ltd. (NASDAQ: EPOW) shares jumped 118.2% to $4.4948. Sunrise New Energy said that the company changed its name from Global Internet of the People, Inc. to Sunrise New Energy effective as of August 10, 2022. Magic Empire Global Limited (NASDAQ: MEGL) shares climbed 80.9% to $14.87 on volatility following the company's IPO earlier this month. Viridian Therapeutics, Inc. (NASDAQ: VRDN) surged 57.7% to $23.23 after the company reported better-than-expected Q2 sales results. The company also announced initial data from the 10mg/kg cohort in its ongoing Phase 1/2 trial of VRDN-001 for thyroid eye disease (TED), a rare autoimmune disease in which the body's immune system attacks the tissues around and behind the eyes. Plus Therapeutics, Inc. (NASDAQ: PSTV) shares jumped 51.7% to $0.8010 as the company presented positive data from ongoing ReSPECT™ clinical trials at the Annual Conference on CNS Clinical Trials and Brain Metastases. Team, Inc. (NYSE: TISI) gained 47.7% to $1.45 after the company announced the sale of its Quest Integrity business to Baker Hughes for $280 million cash. The company also reported Q2 EPS and sales results were up year over year. Regis Corporation (NYSE: RGS) jumped 46% to $1.0610 after the company announced it has amended its credit facility and extended the maturity date from March 23, 2023 to August 31, 2025. GigaMedia Limited (NASDAQ: GIGM) gained 41.6% to $2.32. GigaMedia recently posted a Q2 loss of $0.10 per share. Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) jumped 37.2% to $37.08. Intelligent Living Application Group Inc. (NASDAQ: ILAG) gained 37.1% to $3.73. Tuesday Morning Corporation (NASDAQ: TUEM) rose 28% to $0.3548 after declining around 5% on Friday. Accelerate Diagnostics, Inc. (NASDAQ: AXDX) gained 25% to $2.6599 after the company announced a global commercial collaboration agreement with BD. The company also reported better-than-expected Q2 earnings results. TherapeuticsMD, Inc. (NASDAQ: TXMD) gained 22.2% to $11.25 after the company reported a profit for the second quarter and also announced better-than-expected sales results. Osisko Development Corp. (NYSE: ODV) jumped 21% to $7.36. Osisko Development reported cash position of approximately C$136.3 million as of June 30, 2022. InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) gained 19.7% to $9.71. Blue Apron Holdings, Inc. (NYSE: APRN) surged 17.5% to $4.4785. Lake Street initiated coverage on Blue Apron) with a Buy rating and announced a price target of $9. Alaunos Therapeutics, Inc. (NASDAQ: TCRT) jumped 17% to $1.9400 after the company reported better-than-expected Q2 EPS results. Studio City International Holdings Limited (NYSE: MSC) gained 16.8% to $1.9740. Enhabit, Inc. (NYSE:
Benzinga · Aug 15, 2022
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · Aug 15, 2022
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 87.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · Aug 11, 2022
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
TX
TXMD
TherapeuticsMD, Inc.
Buy
Sell
Market
Limit
Soon
TXMD
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any TXMD yet.
Related Tickers
Earnings